Amgen Inc (AMGN) 122.84 $AMGN
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Sun Jul 27, 6:14AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Final Glance: Biotechnology companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Amgen Announces 2014 Third Quarter Dividend
PR Newswire - Fri Jul 25, 3:00PM CDT
Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014, to all stockholders of record as of the close of business on Aug. 14, 2014.
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Midday Glance: Biotechnology companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
FDA reviewing what could be first biosimilar drug
AP - Thu Jul 24, 4:33PM CDT
WASHINGTON, D.C. (AP) — The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.
Amgen Announces Webcast of 2014 Second Quarter Financial Results
PR Newswire - Thu Jul 24, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Surveyed U.S. and EU5 Dermatologists Indicate that Short-Term and Long-Term Effects on Psoriatic Plaque Clearance are Two Attributes that Most Strongly Influence Prescribing Decisions in Moderate to Severe Psoriasis
PR Newswire - Thu Jul 24, 1:00PM CDT
Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis. Emerging therapies that offer improved effect in these attributes over current therapies would be well received and poised for strong uptake. Based on thought leaders' opinions and clinical trial data, emerging therapies, especially IL-17 inhibitors (Novartis's secukinumab, Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab, Eli Lilly's ixekizumab) have potential, owing to their improved efficacy relative to current therapies in improving psoriatic plaques. However, based on currently available data and physicians' opinions, emerging therapies lack the efficacy, safety and tolerability, and/or delivery features that would allow them to offer better overall clinical profiles than that of Janssen's Stelara.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen
PR Newswire - Thu Jul 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Amgen (Nasdaq:AMGN-Free Report), InterMune (Nasdaq:ITMN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
Cancer Vaccines market set to reach $9 billion by 2022
PRWeb - Sun Jul 27, 6:14AM CDT
With cancer vaccines known to earn higher profits owing to the nature of the disease and the urgency in the demand, SMi's 3rd annual Cancer Vaccines conference comes at the perfect time to explore the latest developments oncolytic vaccines, T cell immune monitoring, cancer immunotherapy, biomarker guided development, plus much more.
Final Glance: Biotechnology companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Amgen Announces 2014 Third Quarter Dividend
PR Newswire - Fri Jul 25, 3:00PM CDT
Amgen (NASDAQ: AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the third quarter of 2014. The dividend will be paid on Sept. 5, 2014, to all stockholders of record as of the close of business on Aug. 14, 2014.
Bayer/Amgen's Nexavar Does Not Show Resilience in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 1:45PM CDT
Bayer (BAYRY) and Amgen's (AMGN) Nexavar performed disppointingly in a late stage study.
Midday Glance: Biotechnology companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Early Glance: Biotechnology companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVAR® (sorafenib) in Patients with Advanced Breast Cancer
PR Newswire - Fri Jul 25, 1:30AM CDT
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ: AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).
FDA reviewing what could be first biosimilar drug
AP - Thu Jul 24, 4:33PM CDT
WASHINGTON, D.C. (AP) — The Food and Drug Administration is reviewing research data on what could become the first U.S.-approved "biosimilar" drug, a cheaper, sort-of generic version of a biologic drug.
Amgen Announces Webcast of 2014 Second Quarter Financial Results
PR Newswire - Thu Jul 24, 3:00PM CDT
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.
Surveyed U.S. and EU5 Dermatologists Indicate that Short-Term and Long-Term Effects on Psoriatic Plaque Clearance are Two Attributes that Most Strongly Influence Prescribing Decisions in Moderate to Severe Psoriasis
PR Newswire - Thu Jul 24, 1:00PM CDT
Decision Resources Group finds that, according to surveyed U.S. and EU5 dermatologists, short-term and long-term effects on psoriatic plaque clearance are two of the attributes that most strongly influence their prescribing decisions in moderate to severe psoriasis. Emerging therapies that offer improved effect in these attributes over current therapies would be well received and poised for strong uptake. Based on thought leaders' opinions and clinical trial data, emerging therapies, especially IL-17 inhibitors (Novartis's secukinumab, Amgen/AstraZeneca/Kyowa Hakko Kirin's brodalumab, Eli Lilly's ixekizumab) have potential, owing to their improved efficacy relative to current therapies in improving psoriatic plaques. However, based on currently available data and physicians' opinions, emerging therapies lack the efficacy, safety and tolerability, and/or delivery features that would allow them to offer better overall clinical profiles than that of Janssen's Stelara.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Stock Market News for July 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 9:10AM CDT
Benchmarks finished mostly higher on Wednesday following upbeat quarterly results from healthcare and technology companies
The Zacks Analyst Blog Highlights: AbbVie, Shire, Amgen, InterMune and Biogen
PR Newswire - Thu Jul 24, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the AbbVie (NYSE:ABBV-Free Report), Shire (Nasdaq:SHPG-Free Report), Amgen (Nasdaq:AMGN-Free Report), InterMune (Nasdaq:ITMN-Free Report) and Biogen (Nasdaq:BIIB-Free Report).
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
Pipeline Analysis and Sales Projections of the Top 25 Pharmaceutical Companies 2013-2023
M2 - Wed Jul 23, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7pjm9m/top_25) has announced the addition of the "Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023" report to their offering. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2023 takes a considered look at the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts which are based on 2013 market conditions. For each company, the report provides: - Revenues - R&D Spending 2007-2013 - Geographic Breakout of Revenues - Performance of Specific Products - Performance by Drug Category - Late-Stage Pipeline - Projections of Revenues to 2023 In addition to specific company data and factors, there are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. The pharmaceutical market as a whole has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. The companies included in the study are: - Pfizer, inc. - Novartis AG - Roche ltd. - Merck & Co., inc. - Sanofi - Glaxosmithkline PLC - Johnson & johnson - Astra Zeneca plc - Eli Lilly and Company - Abbvie, inc. - Teva Pharmaceutical Industries, Ltd. - Amgen, inc. - Bristol-myers Squibb Company - Takeda Pharmaceutical co., LTD - Bayer AG - Novo nordisk - Boehringer Ingelheim gmbh - Daiichi Sankyo - Astellas - Gilead Sciences - Otsuka Pharmaceutical - Merck KGAA - Actavis - Mylan - Baxter international For more information visit http://www.researchandmarkets.com/research/7pjm9m/top_25
